MediWound's groundbreaking Phase III Children Innovative Debridement Study (CIDS) has demonstrated significant advantages of NexoBrid® over standard of care in treating pediatric deep partial- and full-thickness thermal burns. The findings, recently published in Burns journal, showcase the treatment's potential to transform pediatric burn care.
The multicenter study, spanning 36 burn centers across the US, EU, Israel, and India, evaluated 145 pediatric patients from newborn to 18 years of age. Results revealed remarkable improvements in treatment outcomes and patient care approaches.
Clinical Efficacy and Surgical Impact
NexoBrid demonstrated superior efficacy in eschar removal, achieving complete clearance in a median time of one day, compared to six days with standard of care (p < 0.001). The treatment dramatically reduced the need for surgical intervention, with only 8.3% of NexoBrid-treated patients requiring surgical excision, compared to 64.4% in the standard care group.
"Pediatric burn patients account for approximately 30% of all burn cases, and their treatment presents unique challenges," noted Professor Jose Ramón Martínez-Méndez, Head of Burns Unit at University Hospital La Paz, Madrid. "NexoBrid provides a rapid, non-surgical solution that effectively removes eschar while preserving healthy tissue, addressing the critical need to protect viable dermis and improve outcomes for pediatric burn patients."
Key Study Findings
The trial met all co-primary endpoints with statistical significance. The mean percentage of wound area requiring surgical excision was dramatically lower in the NexoBrid group (1.5%) compared to standard care (48.1%, p < 0.001). Long-term follow-up at 12 months showed comparable cosmetic and functional outcomes, with NexoBrid demonstrating better Modified Vancouver Scar Scale scores (3.8 vs 4.9).
Safety Profile and Treatment Efficacy
NexoBrid achieved complete eschar removal in 94.2% of treated patients while maintaining a safety profile comparable to standard care. This enzymatic treatment preserves viable tissue during eschar removal, offering a particularly valuable benefit for pediatric patients where tissue preservation is crucial.
Regulatory Status and Availability
The positive study results have supported NexoBrid's recent label expansion for pediatric use in major markets. The treatment is now approved in more than 40 countries, including the United States, European Union, and Japan, marking a significant advancement in pediatric burn care options.
The development of NexoBrid has received substantial support from the U.S. Biomedical Advanced Research and Development Authority (BARDA), highlighting its strategic importance in medical preparedness and burn treatment advancement.
